Biocon Malaysia Facility Clearance Could Pave Way For US Biosimilar Approvals
Bevacizumab And Insulin Aspart Filings Had Been Held Up By FDA
Biocon Biologics has announced a change in regulatory status for a manufacturing plant in Malaysia that could pave the way for a pair of long-awaited FDA biosimilar approvals, after similar positive news for an Indian site late last year.
